IMMX
Price
$2.62
Change
+$0.14 (+5.65%)
Updated
Oct 15 closing price
Capitalization
86.55M
48 days until earnings call
Intraday Buy/Sell Signals
NUVL
Price
$89.64
Change
+$4.98 (+5.88%)
Updated
Oct 15 closing price
Capitalization
6.47B
21 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

IMMX vs NUVL

Header iconIMMX vs NUVL Comparison
Open Charts IMMX vs NUVLBanner chart's image
Immix Biopharma
Price$2.62
Change+$0.14 (+5.65%)
Volume$492.87K
Capitalization86.55M
Nuvalent
Price$89.64
Change+$4.98 (+5.88%)
Volume$551.21K
Capitalization6.47B
IMMX vs NUVL Comparison Chart in %
IMMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMMX vs. NUVL commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMMX is a Hold and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (IMMX: $2.62 vs. NUVL: $89.71)
Brand notoriety: IMMX and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMMX: 168% vs. NUVL: 134%
Market capitalization -- IMMX: $86.55M vs. NUVL: $6.47B
IMMX [@Biotechnology] is valued at $86.55M. NUVL’s [@Biotechnology] market capitalization is $6.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMMX’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IMMX’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMMX and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMMX’s TA Score shows that 6 TA indicator(s) are bullish while NUVL’s TA Score has 6 bullish TA indicator(s).

  • IMMX’s TA Score: 6 bullish, 4 bearish.
  • NUVL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both IMMX and NUVL are a good buy in the short-term.

Price Growth

IMMX (@Biotechnology) experienced а +3.15% price change this week, while NUVL (@Biotechnology) price change was +5.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +18.20%, and the average quarterly price growth was +82.76%.

Reported Earning Dates

IMMX is expected to report earnings on Dec 03, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.47B) has a higher market cap than IMMX($86.6M). IMMX YTD gains are higher at: 19.091 vs. NUVL (14.601). IMMX has higher annual earnings (EBITDA): -23.58M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. IMMX (11.6M). IMMX (0) and NUVL (0) have equivalent revenues.
IMMXNUVLIMMX / NUVL
Capitalization86.6M6.47B1%
EBITDA-23.58M-362.01M7%
Gain YTD19.09114.601131%
P/E RatioN/AN/A-
Revenue00-
Total Cash11.6M1.01B1%
Total Debt1.04MN/A-
TECHNICAL ANALYSIS
Technical Analysis
IMMXNUVL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 29 days ago
90%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IMMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HAOYX23.83N/A
N/A
Hartford International Opportunities Y
FGREX9.11N/A
N/A
Invesco Global Real Estate R6
TEMIX30.26N/A
N/A
Franklin Mutual International Value A
BLNAX13.75N/A
N/A
Meeder Balanced Adviser
JLGQX91.57N/A
N/A
JPMorgan Large Cap Growth R4

IMMX and

Correlation & Price change

A.I.dvisor tells us that IMMX and IMTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMMX and IMTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMMX
1D Price
Change %
IMMX100%
+5.65%
IMTX - IMMX
32%
Poorly correlated
+6.59%
CRNX - IMMX
30%
Poorly correlated
+0.20%
RNAC - IMMX
30%
Poorly correlated
+2.97%
ATXS - IMMX
30%
Poorly correlated
+2.67%
NUVL - IMMX
30%
Poorly correlated
+5.97%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+5.97%
XENE - NUVL
61%
Loosely correlated
+3.30%
CGON - NUVL
60%
Loosely correlated
+0.56%
RVMD - NUVL
59%
Loosely correlated
+4.34%
XNCR - NUVL
58%
Loosely correlated
+13.44%
IDYA - NUVL
57%
Loosely correlated
+4.86%
More